FKC289 (BCMA/CD19 Dual-Targeted CAR-T) Demonstrates Promising Clinical Efficacy and Safety in Refractory or Relapsed PLA2R-Associated Membranous Nephropathy at ASGCT 2026

From May 11 to 15, 2026, the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT 2026), the largest academic event in the global gene and cell therapy field, will be held in Boston, USA, providing attendees with an international platform to showcase the latest advancements in gene and cell therapies and engage in critical discussions.

Fosun Kite FKC289 (BCMA/CD19 Dual-Target CAR-T) Project Presents Latest Clinical Progress on MN at ASGCT 2026.

FKC289 is one of the key innovative cell therapy products developed by Fosun Kite, designed with a dual-targeting approach based on BCMA/CD19 to further enhance the therapeutic efficacy of CAR-T therapy in complex hematological diseases and autoimmune disease indications.

Abstract Title:Safety and Efficacy of BCMA-CD19 Dual-Target CAR-T Cell Therapy for Refractory or Relapsed PLA2R-Associated Membranous Nephropathy (MN)

Efficacy and Safety of FKC289, a BCMA-CD19 dual-targeted CAR-T therapy for refractory or relapsed PLA2R-associated Membranous Nephropathy

Principal Investigator:Xiang-Hua Huang, Wen-Cui Chen, Wei-Wei Xu, Jin-Zhou Guo, Xiao-Mei Wu, Da-Chang Chen, Wen-Hao Chen, Ai-Dong Shan, Yong Yang, Wen-Shi Wang, Zi-Song Zhou, Gongxian Jia, Yun Liu, Wen Shi, Zhi-Hong Liu

Research Background:Membranous nephropathy (MN) is one of the common causes of nephrotic syndrome in adults. Approximately 30–40% of patients with MN do not respond to initial immunosuppressive therapy or experience relapses, eventually progressing to end-stage renal disease.

Chimeric Antigen Receptor T-cell (CAR-T) therapy has shown significant potential in the treatment of autoimmune diseases and may become a promising therapeutic option for patients with refractory or relapsed (r/r) phospholipase A2 receptor-associated membranous nephropathy (PLA2R-associated MN). This study is an investigator-initiated clinical trial (NCT06285279) that enrolled patients with refractory or relapsed PLA2R-associated MN.

Research Conclusion:The study results indicate that BCMA-CD19 dual-target CAR-T cell therapy can induce rapid and durable immunological remission in patients with refractory or relapsed PLA2R-related membranous nephropathy, further leading to clinical remission and improved renal function.

The treatment was generally well tolerated.

This study provides a promising new therapeutic strategy for the application of BCMA-CD19 dual-target CAR-T therapy in refractory or relapsed membranous nephropathy.

Summary and Future Progress:Currently, the company is continuously advancing the clinical development of FKC289 across multiple indications, aiming to bring innovative treatment options to more patients.

In the future, Fosun Kite will continue to focus on unmet clinical needs, accelerate innovation and transformation in the field of cell therapy, promote more high-quality clinical research results to the international authoritative stage, and provide more valuable treatment options for patients worldwide.

Contact Information

Media:pr@fosunpharma.com

Investor:ir@fosunpharma.com